#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0003] Virus and nucleic acid vectors provide a means to deliver nucleic acid sequences to cells, and they are widely used in gene therapy applications.
1-1	0-1	[	_	_	
1-2	1-5	0003	_	_	
1-3	5-6	]	_	_	
1-4	7-12	Virus	_	_	
1-5	13-16	and	_	_	
1-6	17-24	nucleic	_	_	
1-7	25-29	acid	_	_	
1-8	30-37	vectors	_	_	
1-9	38-45	provide	_	_	
1-10	46-47	a	_	_	
1-11	48-53	means	_	_	
1-12	54-56	to	_	_	
1-13	57-64	deliver	_	_	
1-14	65-72	nucleic	_	_	
1-15	73-77	acid	_	_	
1-16	78-87	sequences	_	_	
1-17	88-90	to	_	_	
1-18	91-96	cells	_	_	
1-19	96-97	,	_	_	
1-20	98-101	and	_	_	
1-21	102-106	they	_	_	
1-22	107-110	are	_	_	
1-23	111-117	widely	_	_	
1-24	118-122	used	_	_	
1-25	123-125	in	_	_	
1-26	126-130	gene	_	_	
1-27	131-138	therapy	_	_	
1-28	139-151	applications	_	_	
1-29	151-152	.	_	_	

#Text=Critical to effective gene therapy is the ability to establish efficient expression of an Exogenous Nucleic Acid(s) in the target cell.
2-1	153-161	Critical	_	_	
2-2	162-164	to	_	_	
2-3	165-174	effective	_	_	
2-4	175-179	gene	_	_	
2-5	180-187	therapy	_	_	
2-6	188-190	is	_	_	
2-7	191-194	the	_	_	
2-8	195-202	ability	_	_	
2-9	203-205	to	_	_	
2-10	206-215	establish	_	_	
2-11	216-225	efficient	_	_	
2-12	226-236	expression	_	_	
2-13	237-239	of	_	_	
2-14	240-242	an	_	_	
2-15	243-252	Exogenous	_	_	
2-16	253-260	Nucleic	_	_	
2-17	261-265	Acid	_	_	
2-18	265-266	(	_	_	
2-19	266-267	s	_	_	
2-20	267-268	)	_	_	
2-21	269-271	in	_	_	
2-22	272-275	the	_	_	
2-23	276-282	target	_	_	
2-24	283-287	cell	_	_	
2-25	287-288	.	_	_	

#Text=Expression of exogenous nucleic acid in target cells can take place when the Exogenous Nucleic Acid(s) is/are either in an integrated or in an episomal state.
3-1	289-299	Expression	_	_	
3-2	300-302	of	_	_	
3-3	303-312	exogenous	_	_	
3-4	313-320	nucleic	_	_	
3-5	321-325	acid	_	_	
3-6	326-328	in	_	_	
3-7	329-335	target	_	_	
3-8	336-341	cells	_	_	
3-9	342-345	can	_	_	
3-10	346-350	take	_	_	
3-11	351-356	place	_	_	
3-12	357-361	when	_	_	
3-13	362-365	the	_	_	
3-14	366-375	Exogenous	_	_	
3-15	376-383	Nucleic	_	_	
3-16	384-388	Acid	_	_	
3-17	388-389	(	_	_	
3-18	389-390	s	_	_	
3-19	390-391	)	_	_	
3-20	392-394	is	_	_	
3-21	394-395	/	_	_	
3-22	395-398	are	_	_	
3-23	399-405	either	_	_	
3-24	406-408	in	_	_	
3-25	409-411	an	_	_	
3-26	412-422	integrated	_	_	
3-27	423-425	or	_	_	
3-28	426-428	in	_	_	
3-29	429-431	an	_	_	
3-30	432-440	episomal	_	_	
3-31	441-446	state	_	_	
3-32	446-447	.	_	_	

#Text=Although expression in the episomal state can take place in target cells, expression in most cases persists for only limited periods of time.
4-1	448-456	Although	_	_	
4-2	457-467	expression	_	_	
4-3	468-470	in	_	_	
4-4	471-474	the	_	_	
4-5	475-483	episomal	_	_	
4-6	484-489	state	_	_	
4-7	490-493	can	_	_	
4-8	494-498	take	_	_	
4-9	499-504	place	_	_	
4-10	505-507	in	_	_	
4-11	508-514	target	_	_	
4-12	515-520	cells	_	_	
4-13	520-521	,	_	_	
4-14	522-532	expression	_	_	
4-15	533-535	in	_	_	
4-16	536-540	most	_	_	
4-17	541-546	cases	_	_	
4-18	547-555	persists	_	_	
4-19	556-559	for	_	_	
4-20	560-564	only	_	_	
4-21	565-572	limited	_	_	
4-22	573-580	periods	_	_	
4-23	581-583	of	_	_	
4-24	584-588	time	_	_	
4-25	588-589	.	_	_	

#Text=In contrast, the expression of Exogenous Nucleic Acids in an integrated state can be maintained for much longer periods.
#Text=[0004] Certain viruses have been of particular interest for use as vectors in gene therapy because of their ability to efficiently transfer and/or establish stable expression of Exogenous Nucleic Acid in the target cell.
5-1	590-592	In	_	_	
5-2	593-601	contrast	_	_	
5-3	601-602	,	_	_	
5-4	603-606	the	_	_	
5-5	607-617	expression	_	_	
5-6	618-620	of	_	_	
5-7	621-630	Exogenous	_	_	
5-8	631-638	Nucleic	_	_	
5-9	639-644	Acids	_	_	
5-10	645-647	in	_	_	
5-11	648-650	an	_	_	
5-12	651-661	integrated	_	_	
5-13	662-667	state	_	_	
5-14	668-671	can	_	_	
5-15	672-674	be	_	_	
5-16	675-685	maintained	_	_	
5-17	686-689	for	_	_	
5-18	690-694	much	_	_	
5-19	695-701	longer	_	_	
5-20	702-709	periods	_	_	
5-21	709-710	.	_	_	
5-22	711-712	[	_	_	
5-23	712-716	0004	_	_	
5-24	716-717	]	_	_	
5-25	718-725	Certain	_	_	
5-26	726-733	viruses	_	_	
5-27	734-738	have	_	_	
5-28	739-743	been	_	_	
5-29	744-746	of	_	_	
5-30	747-757	particular	_	_	
5-31	758-766	interest	_	_	
5-32	767-770	for	_	_	
5-33	771-774	use	_	_	
5-34	775-777	as	_	_	
5-35	778-785	vectors	_	_	
5-36	786-788	in	_	_	
5-37	789-793	gene	_	_	
5-38	794-801	therapy	_	_	
5-39	802-809	because	_	_	
5-40	810-812	of	_	_	
5-41	813-818	their	_	_	
5-42	819-826	ability	_	_	
5-43	827-829	to	_	_	
5-44	830-841	efficiently	_	_	
5-45	842-850	transfer	_	_	
5-46	851-854	and	_	_	
5-47	854-855	/	_	_	
5-48	855-857	or	_	_	
5-49	858-867	establish	_	_	
5-50	868-874	stable	_	_	
5-51	875-885	expression	_	_	
5-52	886-888	of	_	_	
5-53	889-898	Exogenous	_	_	
5-54	899-906	Nucleic	_	_	
5-55	907-911	Acid	_	_	
5-56	912-914	in	_	_	
5-57	915-918	the	_	_	
5-58	919-925	target	_	_	
5-59	926-930	cell	_	_	
5-60	930-931	.	_	_	

#Text=Although each particular family of virus may possess elements that confer specific advantages for development into a virus vector, each virus family also contains inherent features that limit its use as a viable means of human gene transfer.
#Text=[0005] Retroviruses have been a focus for development into virus vectors because they can establish stable integration of viral sequences.
6-1	932-940	Although	_	_	
6-2	941-945	each	_	_	
6-3	946-956	particular	_	_	
6-4	957-963	family	_	_	
6-5	964-966	of	_	_	
6-6	967-972	virus	_	_	
6-7	973-976	may	_	_	
6-8	977-984	possess	_	_	
6-9	985-993	elements	_	_	
6-10	994-998	that	_	_	
6-11	999-1005	confer	_	_	
6-12	1006-1014	specific	_	_	
6-13	1015-1025	advantages	_	_	
6-14	1026-1029	for	_	_	
6-15	1030-1041	development	_	_	
6-16	1042-1046	into	_	_	
6-17	1047-1048	a	_	_	
6-18	1049-1054	virus	_	_	
6-19	1055-1061	vector	_	_	
6-20	1061-1062	,	_	_	
6-21	1063-1067	each	_	_	
6-22	1068-1073	virus	_	_	
6-23	1074-1080	family	_	_	
6-24	1081-1085	also	_	_	
6-25	1086-1094	contains	_	_	
6-26	1095-1103	inherent	_	_	
6-27	1104-1112	features	_	_	
6-28	1113-1117	that	_	_	
6-29	1118-1123	limit	_	_	
6-30	1124-1127	its	_	_	
6-31	1128-1131	use	_	_	
6-32	1132-1134	as	_	_	
6-33	1135-1136	a	_	_	
6-34	1137-1143	viable	_	_	
6-35	1144-1149	means	_	_	
6-36	1150-1152	of	_	_	
6-37	1153-1158	human	_	_	
6-38	1159-1163	gene	_	_	
6-39	1164-1172	transfer	_	_	
6-40	1172-1173	.	_	_	
6-41	1174-1175	[	_	_	
6-42	1175-1179	0005	_	_	
6-43	1179-1180	]	_	_	
6-44	1181-1193	Retroviruses	_	_	
6-45	1194-1198	have	_	_	
6-46	1199-1203	been	_	_	
6-47	1204-1205	a	_	_	
6-48	1206-1211	focus	_	_	
6-49	1212-1215	for	_	_	
6-50	1216-1227	development	_	_	
6-51	1228-1232	into	_	_	
6-52	1233-1238	virus	_	_	
6-53	1239-1246	vectors	_	_	
6-54	1247-1254	because	_	_	
6-55	1255-1259	they	_	_	
6-56	1260-1263	can	_	_	
6-57	1264-1273	establish	_	_	
6-58	1274-1280	stable	_	_	
6-59	1281-1292	integration	_	_	
6-60	1293-1295	of	_	_	
6-61	1296-1301	viral	_	_	
6-62	1302-1311	sequences	_	_	
6-63	1311-1312	.	_	_	

#Text=Current retroviral vectors can be produced from packaging cells in which the gag, pol and env elements are provided in trans through a plasmid or mutated virus.
7-1	1313-1320	Current	_	_	
7-2	1321-1331	retroviral	_	_	
7-3	1332-1339	vectors	_	_	
7-4	1340-1343	can	_	_	
7-5	1344-1346	be	_	_	
7-6	1347-1355	produced	_	_	
7-7	1356-1360	from	_	_	
7-8	1361-1370	packaging	_	_	
7-9	1371-1376	cells	_	_	
7-10	1377-1379	in	_	_	
7-11	1380-1385	which	_	_	
7-12	1386-1389	the	_	_	
7-13	1390-1393	gag	_	_	
7-14	1393-1394	,	_	_	
7-15	1395-1398	pol	_	_	
7-16	1399-1402	and	_	_	
7-17	1403-1406	env	_	_	
7-18	1407-1415	elements	_	_	
7-19	1416-1419	are	_	_	
7-20	1420-1428	provided	_	_	
7-21	1429-1431	in	_	_	
7-22	1432-1437	trans	_	_	
7-23	1438-1445	through	_	_	
7-24	1446-1447	a	_	_	
7-25	1448-1455	plasmid	_	_	
7-26	1456-1458	or	_	_	
7-27	1459-1466	mutated	_	_	
7-28	1467-1472	virus	_	_	
7-29	1472-1473	.	_	_	

#Text=These vectors can transduce sequences of up to 7.5 to 8.0 kilobases.
8-1	1474-1479	These	_	_	
8-2	1480-1487	vectors	_	_	
8-3	1488-1491	can	_	_	
8-4	1492-1501	transduce	_	_	
8-5	1502-1511	sequences	_	_	
8-6	1512-1514	of	_	_	
8-7	1515-1517	up	_	_	
8-8	1518-1520	to	_	_	
8-9	1521-1524	7.5	_	_	
8-10	1525-1527	to	_	_	
8-11	1528-1531	8.0	_	_	
8-12	1532-1541	kilobases	_	_	
8-13	1541-1542	.	_	_	

#Text=Nevertheless, several intrinsic features of retroviruses have hindered their use as virus vectors, and efforts to modify them to produce safe and efficient vectors have led to low yields of virus vector or to the inefficient expression of the exogenous gene in the target cell.
9-1	1543-1555	Nevertheless	_	_	
9-2	1555-1556	,	_	_	
9-3	1557-1564	several	_	_	
9-4	1565-1574	intrinsic	_	_	
9-5	1575-1583	features	_	_	
9-6	1584-1586	of	_	_	
9-7	1587-1599	retroviruses	_	_	
9-8	1600-1604	have	_	_	
9-9	1605-1613	hindered	_	_	
9-10	1614-1619	their	_	_	
9-11	1620-1623	use	_	_	
9-12	1624-1626	as	_	_	
9-13	1627-1632	virus	_	_	
9-14	1633-1640	vectors	_	_	
9-15	1640-1641	,	_	_	
9-16	1642-1645	and	_	_	
9-17	1646-1653	efforts	_	_	
9-18	1654-1656	to	_	_	
9-19	1657-1663	modify	_	_	
9-20	1664-1668	them	_	_	
9-21	1669-1671	to	_	_	
9-22	1672-1679	produce	_	_	
9-23	1680-1684	safe	_	_	
9-24	1685-1688	and	_	_	
9-25	1689-1698	efficient	_	_	
9-26	1699-1706	vectors	_	_	
9-27	1707-1711	have	_	_	
9-28	1712-1715	led	_	_	
9-29	1716-1718	to	_	_	
9-30	1719-1722	low	_	_	
9-31	1723-1729	yields	_	_	
9-32	1730-1732	of	_	_	
9-33	1733-1738	virus	_	_	
9-34	1739-1745	vector	_	_	
9-35	1746-1748	or	_	_	
9-36	1749-1751	to	_	_	
9-37	1752-1755	the	_	_	
9-38	1756-1767	inefficient	_	_	
9-39	1768-1778	expression	_	_	
9-40	1779-1781	of	_	_	
9-41	1782-1785	the	_	_	
9-42	1786-1795	exogenous	_	_	
9-43	1796-1800	gene	_	_	
9-44	1801-1803	in	_	_	
9-45	1804-1807	the	_	_	
9-46	1808-1814	target	_	_	
9-47	1815-1819	cell	_	_	
9-48	1819-1820	.	_	_	

#Text=[Morgenstern, J.
10-1	1821-1822	[	_	_	
10-2	1822-1833	Morgenstern	_	_	
10-3	1833-1834	,	_	_	
10-4	1835-1836	J	_	_	
10-5	1836-1837	.	_	_	

#Text=P. and Land, Hartmut Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols, 1991, edited by: E.
11-1	1838-1839	P	_	_	
11-2	1839-1840	.	_	_	
11-3	1841-1844	and	_	_	
11-4	1845-1849	Land	_	_	
11-5	1849-1850	,	_	_	
11-6	1851-1858	Hartmut	_	_	
11-7	1859-1866	Methods	_	_	
11-8	1867-1869	in	_	_	
11-9	1870-1879	Molecular	_	_	
11-10	1880-1887	Biology	_	_	
11-11	1887-1888	,	_	_	
11-12	1889-1892	Vol	_	_	
11-13	1892-1893	.	_	_	
11-14	1894-1895	7	_	_	
11-15	1895-1896	:	_	_	
11-16	1897-1901	Gene	_	_	
11-17	1902-1910	Transfer	_	_	
11-18	1911-1914	and	_	_	
11-19	1915-1925	Expression	_	_	
11-20	1926-1935	Protocols	_	_	
11-21	1935-1936	,	_	_	
11-22	1937-1941	1991	_	_	
11-23	1941-1942	,	_	_	
11-24	1943-1949	edited	_	_	
11-25	1950-1952	by	_	_	
11-26	1952-1953	:	_	_	
11-27	1954-1955	E	_	_	
11-28	1955-1956	.	_	_	

#Text=J.
12-1	1957-1958	J	_	_	
12-2	1958-1959	.	_	_	

#Text=Murray The Humana Press Inc., Clifton, N.J.; Anderson, W F Science 256:808-813 (1992); Mulligan, R C Science 260:926-932 (1993)1; Smith, A E, Ann Rev.
13-1	1960-1966	Murray	_	_	
13-2	1967-1970	The	_	_	
13-3	1971-1977	Humana	_	_	
13-4	1978-1983	Press	_	_	
13-5	1984-1987	Inc	_	_	
13-6	1987-1988	.	_	_	
13-7	1988-1989	,	_	_	
13-8	1990-1997	Clifton	_	_	
13-9	1997-1998	,	_	_	
13-10	1999-2002	N.J	_	_	
13-11	2002-2003	.	_	_	
13-12	2003-2004	;	_	_	
13-13	2005-2013	Anderson	_	_	
13-14	2013-2014	,	_	_	
13-15	2015-2016	W	_	_	
13-16	2017-2018	F	_	_	
13-17	2019-2026	Science	_	_	
13-18	2027-2030	256	_	_	
13-19	2030-2031	:	_	_	
13-20	2031-2034	808	_	_	
13-21	2034-2035	-	_	_	
13-22	2035-2038	813	_	_	
13-23	2039-2040	(	_	_	
13-24	2040-2044	1992	_	_	
13-25	2044-2045	)	_	_	
13-26	2045-2046	;	_	_	
13-27	2047-2055	Mulligan	_	_	
13-28	2055-2056	,	_	_	
13-29	2057-2058	R	_	_	
13-30	2059-2060	C	_	_	
13-31	2061-2068	Science	_	_	
13-32	2069-2072	260	_	_	
13-33	2072-2073	:	_	_	
13-34	2073-2076	926	_	_	
13-35	2076-2077	-	_	_	
13-36	2077-2080	932	_	_	
13-37	2081-2082	(	_	_	
13-38	2082-2086	1993	_	_	
13-39	2086-2087	)	_	_	
13-40	2087-2088	1	_	_	
13-41	2088-2089	;	_	_	
13-42	2090-2095	Smith	_	_	
13-43	2095-2096	,	_	_	
13-44	2097-2098	A	_	_	
13-45	2099-2100	E	_	_	
13-46	2100-2101	,	_	_	
13-47	2102-2105	Ann	_	_	
13-48	2106-2109	Rev	_	_	
13-49	2109-2110	.	_	_	

#Text=Microbiol. 49:807-838: Muzyczka, N., Curr.
14-1	2111-2120	Microbiol	_	_	
14-2	2120-2121	.	_	_	
14-3	2122-2124	49	_	_	
14-4	2124-2125	:	_	_	
14-5	2125-2128	807	_	_	
14-6	2128-2129	-	_	_	
14-7	2129-2132	838	_	_	
14-8	2132-2133	:	_	_	
14-9	2134-2142	Muzyczka	_	_	
14-10	2142-2143	,	_	_	
14-11	2144-2145	N	_	_	
14-12	2145-2146	.	_	_	
14-13	2146-2147	,	_	_	
14-14	2148-2152	Curr	_	_	
14-15	2152-2153	.	_	_	

#Text=Top.
15-1	2154-2157	Top	_	_	
15-2	2157-2158	.	_	_	

#Text=Microbiol.
16-1	2159-2168	Microbiol	_	_	
16-2	2168-2169	.	_	_	

#Text=Immunol. 158:97-129(1992); Kotin, R.
17-1	2170-2177	Immunol	_	_	
17-2	2177-2178	.	_	_	
17-3	2179-2182	158	_	_	
17-4	2182-2183	:	_	_	
17-5	2183-2185	97	_	_	
17-6	2185-2186	-	_	_	
17-7	2186-2189	129	_	_	
17-8	2189-2190	(	_	_	
17-9	2190-2194	1992	_	_	
17-10	2194-2195	)	_	_	
17-11	2195-2196	;	_	_	
17-12	2197-2202	Kotin	_	_	
17-13	2202-2203	,	_	_	
17-14	2204-2205	R	_	_	
17-15	2205-2206	.	_	_	

#Text=M., Human Gene Ther. 5:793-801 (1994); and Berliner, K.
18-1	2207-2208	M	_	_	
18-2	2208-2209	.	_	_	
18-3	2209-2210	,	_	_	
18-4	2211-2216	Human	_	_	
18-5	2217-2221	Gene	_	_	
18-6	2222-2226	Ther	_	_	
18-7	2226-2227	.	_	_	
18-8	2228-2229	5	_	_	
18-9	2229-2230	:	_	_	
18-10	2230-2233	793	_	_	
18-11	2233-2234	-	_	_	
18-12	2234-2237	801	_	_	
18-13	2238-2239	(	_	_	
18-14	2239-2243	1994	_	_	
18-15	2243-2244	)	_	_	
18-16	2244-2245	;	_	_	
18-17	2246-2249	and	_	_	
18-18	2250-2258	Berliner	_	_	
18-19	2258-2259	,	_	_	
18-20	2260-2261	K	_	_	
18-21	2261-2262	.	_	_	

#Text=L., Curr.
19-1	2263-2264	L	_	_	
19-2	2264-2265	.	_	_	
19-3	2265-2266	,	_	_	
19-4	2267-2271	Curr	_	_	
19-5	2271-2272	.	_	_	

#Text=Top.
20-1	2273-2276	Top	_	_	
20-2	2276-2277	.	_	_	

#Text=Microbiol.
21-1	2278-2287	Microbiol	_	_	
21-2	2287-2288	.	_	_	

#Text=Immunol. 158:39-66 (1992)].
22-1	2289-2296	Immunol	_	_	
22-2	2296-2297	.	_	_	
22-3	2298-2301	158	_	_	
22-4	2301-2302	:	_	_	
22-5	2302-2304	39	_	_	
22-6	2304-2305	-	_	_	
22-7	2305-2307	66	_	_	
22-8	2308-2309	(	_	_	
22-9	2309-2313	1992	_	_	
22-10	2313-2314	)	_	_	
22-11	2314-2315	]	_	_	
22-12	2315-2316	.	_	_	

#Text=The contents of the foregoing book and publications are incorporated herein by reference.
23-1	2317-2320	The	_	_	
23-2	2321-2329	contents	_	_	
23-3	2330-2332	of	_	_	
23-4	2333-2336	the	_	_	
23-5	2337-2346	foregoing	_	_	
23-6	2347-2351	book	_	_	
23-7	2352-2355	and	_	_	
23-8	2356-2368	publications	_	_	
23-9	2369-2372	are	_	_	
23-10	2373-2385	incorporated	_	_	
23-11	2386-2392	herein	_	_	
23-12	2393-2395	by	_	_	
23-13	2396-2405	reference	_	_	
23-14	2405-2406	.	_	_	

#Text=For example, it has been demonstrated that in retrovirus vectors the level of expression directed by an internal promoter/enhancer can be suppressed up to 50-fold by the flanking LTRs, presumably as a result of interference between transcriptional regulatory units.
24-1	2407-2410	For	_	_	
24-2	2411-2418	example	_	_	
24-3	2418-2419	,	_	_	
24-4	2420-2422	it	_	_	
24-5	2423-2426	has	_	_	
24-6	2427-2431	been	_	_	
24-7	2432-2444	demonstrated	_	_	
24-8	2445-2449	that	_	_	
24-9	2450-2452	in	_	_	
24-10	2453-2463	retrovirus	_	_	
24-11	2464-2471	vectors	_	_	
24-12	2472-2475	the	_	_	
24-13	2476-2481	level	_	_	
24-14	2482-2484	of	_	_	
24-15	2485-2495	expression	_	_	
24-16	2496-2504	directed	_	_	
24-17	2505-2507	by	_	_	
24-18	2508-2510	an	_	_	
24-19	2511-2519	internal	_	_	
24-20	2520-2528	promoter	_	_	
24-21	2528-2529	/	_	_	
24-22	2529-2537	enhancer	_	_	
24-23	2538-2541	can	_	_	
24-24	2542-2544	be	_	_	
24-25	2545-2555	suppressed	_	_	
24-26	2556-2558	up	_	_	
24-27	2559-2561	to	_	_	
24-28	2562-2564	50	_	_	
24-29	2564-2565	-	_	_	
24-30	2565-2569	fold	_	_	
24-31	2570-2572	by	_	_	
24-32	2573-2576	the	_	_	
24-33	2577-2585	flanking	_	_	
24-34	2586-2590	LTRs	_	_	
24-35	2590-2591	,	_	_	
24-36	2592-2602	presumably	_	_	
24-37	2603-2605	as	_	_	
24-38	2606-2607	a	_	_	
24-39	2608-2614	result	_	_	
24-40	2615-2617	of	_	_	
24-41	2618-2630	interference	_	_	
24-42	2631-2638	between	_	_	
24-43	2639-2654	transcriptional	_	_	
24-44	2655-2665	regulatory	_	_	
24-45	2666-2671	units	_	_	
24-46	2671-2672	.	_	_	

#Text=[Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols Edited by: E.
25-1	2673-2674	[	_	_	
25-2	2674-2681	Methods	_	_	
25-3	2682-2684	in	_	_	
25-4	2685-2694	Molecular	_	_	
25-5	2695-2702	Biology	_	_	
25-6	2702-2703	,	_	_	
25-7	2704-2707	Vol	_	_	
25-8	2707-2708	.	_	_	
25-9	2709-2710	7	_	_	
25-10	2710-2711	:	_	_	
25-11	2712-2716	Gene	_	_	
25-12	2717-2725	Transfer	_	_	
25-13	2726-2729	and	_	_	
25-14	2730-2740	Expression	_	_	
25-15	2741-2750	Protocols	_	_	
25-16	2751-2757	Edited	_	_	
25-17	2758-2760	by	_	_	
25-18	2760-2761	:	_	_	
25-19	2762-2763	E	_	_	
25-20	2763-2764	.	_	_	

#Text=J.
26-1	2765-2766	J	_	_	
26-2	2766-2767	.	_	_	

#Text=Murray The Humana Press, Inc.
27-1	2768-2774	Murray	_	_	
27-2	2775-2778	The	_	_	
27-3	2779-2785	Humana	_	_	
27-4	2786-2791	Press	_	_	
27-5	2791-2792	,	_	_	
27-6	2793-2796	Inc	_	_	
27-7	2796-2797	.	_	_	

#Text=Clifton, N.J. (1991), supra; Emerman, M. and Temin, H.
28-1	2798-2805	Clifton	_	_	
28-2	2805-2806	,	_	_	
28-3	2807-2810	N.J	_	_	
28-4	2810-2811	.	_	_	
28-5	2812-2813	(	_	_	
28-6	2813-2817	1991	_	_	
28-7	2817-2818	)	_	_	
28-8	2818-2819	,	_	_	
28-9	2820-2825	supra	_	_	
28-10	2825-2826	;	_	_	
28-11	2827-2834	Emerman	_	_	
28-12	2834-2835	,	_	_	
28-13	2836-2837	M	_	_	
28-14	2837-2838	.	_	_	
28-15	2839-2842	and	_	_	
28-16	2843-2848	Temin	_	_	
28-17	2848-2849	,	_	_	
28-18	2850-2851	H	_	_	
28-19	2851-2852	.	_	_	

#Text=M., Cell 39:459-467 (1984); Emerman, M. and Temin, H.
29-1	2853-2854	M	_	_	
29-2	2854-2855	.	_	_	
29-3	2855-2856	,	_	_	
29-4	2857-2861	Cell	_	_	
29-5	2862-2864	39	_	_	
29-6	2864-2865	:	_	_	
29-7	2865-2868	459	_	_	
29-8	2868-2869	-	_	_	
29-9	2869-2872	467	_	_	
29-10	2873-2874	(	_	_	
29-11	2874-2878	1984	_	_	
29-12	2878-2879	)	_	_	
29-13	2879-2880	;	_	_	
29-14	2881-2888	Emerman	_	_	
29-15	2888-2889	,	_	_	
29-16	2890-2891	M	_	_	
29-17	2891-2892	.	_	_	
29-18	2893-2896	and	_	_	
29-19	2897-2902	Temin	_	_	
29-20	2902-2903	,	_	_	
29-21	2904-2905	H	_	_	
29-22	2905-2906	.	_	_	

#Text=M., Mol.
30-1	2907-2908	M	_	_	
30-2	2908-2909	.	_	_	
30-3	2909-2910	,	_	_	
30-4	2911-2914	Mol	_	_	
30-5	2914-2915	.	_	_	

#Text=Cell.
31-1	2916-2920	Cell	_	_	
31-2	2920-2921	.	_	_	

#Text=Bio. 6:792-800 (1986); Emerman, M. and Temin, H.
32-1	2922-2925	Bio	_	_	
32-2	2925-2926	.	_	_	
32-3	2927-2928	6	_	_	
32-4	2928-2929	:	_	_	
32-5	2929-2932	792	_	_	
32-6	2932-2933	-	_	_	
32-7	2933-2936	800	_	_	
32-8	2937-2938	(	_	_	
32-9	2938-2942	1986	_	_	
32-10	2942-2943	)	_	_	
32-11	2943-2944	;	_	_	
32-12	2945-2952	Emerman	_	_	
32-13	2952-2953	,	_	_	
32-14	2954-2955	M	_	_	
32-15	2955-2956	.	_	_	
32-16	2957-2960	and	_	_	
32-17	2961-2966	Temin	_	_	
32-18	2966-2967	,	_	_	
32-19	2968-2969	H	_	_	
32-20	2969-2970	.	_	_	

#Text=M., Nucleic Acids Res. 14:9381-9396 (1986)].
33-1	2971-2972	M	_	_	
33-2	2972-2973	.	_	_	
33-3	2973-2974	,	_	_	
33-4	2975-2982	Nucleic	_	_	
33-5	2983-2988	Acids	_	_	
33-6	2989-2992	Res	_	_	
33-7	2992-2993	.	_	_	
33-8	2994-2996	14	_	_	
33-9	2996-2997	:	_	_	
33-10	2997-3001	9381	_	_	
33-11	3001-3002	-	_	_	
33-12	3002-3006	9396	_	_	
33-13	3007-3008	(	_	_	
33-14	3008-3012	1986	_	_	
33-15	3012-3013	)	_	_	
33-16	3013-3014	]	_	_	
33-17	3014-3015	.	_	_	

#Text=The foregoing book and publications are also incorporated herein by reference.
34-1	3016-3019	The	_	_	
34-2	3020-3029	foregoing	_	_	
34-3	3030-3034	book	_	_	
34-4	3035-3038	and	_	_	
34-5	3039-3051	publications	_	_	
34-6	3052-3055	are	_	_	
34-7	3056-3060	also	_	_	
34-8	3061-3073	incorporated	_	_	
34-9	3074-3080	herein	_	_	
34-10	3081-3083	by	_	_	
34-11	3084-3093	reference	_	_	
34-12	3093-3094	.	_	_	

#Text=Attempts to overcome this suppression and achieve maximum expression of the exogenous nucleic acid have been made by deletion of the promoter and enhancer sequences within the U3 region of the 3' LTR in the provirus [Yu, S.
35-1	3095-3103	Attempts	_	_	
35-2	3104-3106	to	_	_	
35-3	3107-3115	overcome	_	_	
35-4	3116-3120	this	_	_	
35-5	3121-3132	suppression	_	_	
35-6	3133-3136	and	_	_	
35-7	3137-3144	achieve	_	_	
35-8	3145-3152	maximum	_	_	
35-9	3153-3163	expression	_	_	
35-10	3164-3166	of	_	_	
35-11	3167-3170	the	_	_	
35-12	3171-3180	exogenous	_	_	
35-13	3181-3188	nucleic	_	_	
35-14	3189-3193	acid	_	_	
35-15	3194-3198	have	_	_	
35-16	3199-3203	been	_	_	
35-17	3204-3208	made	_	_	
35-18	3209-3211	by	_	_	
35-19	3212-3220	deletion	_	_	
35-20	3221-3223	of	_	_	
35-21	3224-3227	the	_	_	
35-22	3228-3236	promoter	_	_	
35-23	3237-3240	and	_	_	
35-24	3241-3249	enhancer	_	_	
35-25	3250-3259	sequences	_	_	
35-26	3260-3266	within	_	_	
35-27	3267-3270	the	_	_	
35-28	3271-3273	U3	_	_	
35-29	3274-3280	region	_	_	
35-30	3281-3283	of	_	_	
35-31	3284-3287	the	_	_	
35-32	3288-3289	3	_	_	
35-33	3289-3290	'	_	_	
35-34	3291-3294	LTR	_	_	
35-35	3295-3297	in	_	_	
35-36	3298-3301	the	_	_	
35-37	3302-3310	provirus	_	_	
35-38	3311-3312	[	_	_	
35-39	3312-3314	Yu	_	_	
35-40	3314-3315	,	_	_	
35-41	3316-3317	S	_	_	
35-42	3317-3318	.	_	_	

#Text=F. et al.
36-1	3319-3320	F	_	_	
36-2	3320-3321	.	_	_	
36-3	3322-3324	et	_	_	
36-4	3325-3327	al	_	_	
36-5	3327-3328	.	_	_	

#Text=Proc.
37-1	3329-3333	Proc	_	_	
37-2	3333-3334	.	_	_	

#Text=Natl.
38-1	3335-3339	Natl	_	_	
38-2	3339-3340	.	_	_	

#Text=Acad.
39-1	3341-3345	Acad	_	_	
39-2	3345-3346	.	_	_	

#Text=Sci.
40-1	3347-3350	Sci	_	_	
40-2	3350-3351	.	_	_	

#Text=USA 83:3194-3198 (1986); Hawley, R.
41-1	3352-3355	USA	_	_	
41-2	3356-3358	83	_	_	
41-3	3358-3359	:	_	_	
41-4	3359-3363	3194	_	_	
41-5	3363-3364	-	_	_	
41-6	3364-3368	3198	_	_	
41-7	3369-3370	(	_	_	
41-8	3370-3374	1986	_	_	
41-9	3374-3375	)	_	_	
41-10	3375-3376	;	_	_	
41-11	3377-3383	Hawley	_	_	
41-12	3383-3384	,	_	_	
41-13	3385-3386	R	_	_	
41-14	3386-3387	.	_	_	

#Text=G. et al.
42-1	3388-3389	G	_	_	
42-2	3389-3390	.	_	_	
42-3	3391-3393	et	_	_	
42-4	3394-3396	al	_	_	
42-5	3396-3397	.	_	_	

#Text=Proc.
43-1	3398-3402	Proc	_	_	
43-2	3402-3403	.	_	_	

#Text=Natl.
44-1	3404-3408	Natl	_	_	
44-2	3408-3409	.	_	_	

#Text=Acad.
45-1	3410-3414	Acad	_	_	
45-2	3414-3415	.	_	_	

#Text=Sci.
46-1	3416-3419	Sci	_	_	
46-2	3419-3420	.	_	_	

#Text=USA 84:2406-2410 (1987); Yee, J.
47-1	3421-3424	USA	_	_	
47-2	3425-3427	84	_	_	
47-3	3427-3428	:	_	_	
47-4	3428-3432	2406	_	_	
47-5	3432-3433	-	_	_	
47-6	3433-3437	2410	_	_	
47-7	3438-3439	(	_	_	
47-8	3439-3443	1987	_	_	
47-9	3443-3444	)	_	_	
47-10	3444-3445	;	_	_	
47-11	3446-3449	Yee	_	_	
47-12	3449-3450	,	_	_	
47-13	3451-3452	J	_	_	
47-14	3452-3453	.	_	_	

#Text=K. et al.
48-1	3454-3455	K	_	_	
48-2	3455-3456	.	_	_	
48-3	3457-3459	et	_	_	
48-4	3460-3462	al	_	_	
48-5	3462-3463	.	_	_	

#Text=Proc.
49-1	3464-3468	Proc	_	_	
49-2	3468-3469	.	_	_	

#Text=Natl.
50-1	3470-3474	Natl	_	_	
50-2	3474-3475	.	_	_	

#Text=Acad.
51-1	3476-3480	Acad	_	_	
51-2	3480-3481	.	_	_	

#Text=Sci.
52-1	3482-3485	Sci	_	_	
52-2	3485-3486	.	_	_	

#Text=USA 84:5197-5201 (1987)].
53-1	3487-3490	USA	_	_	
53-2	3491-3493	84	_	_	
53-3	3493-3494	:	_	_	
53-4	3494-3498	5197	_	_	
53-5	3498-3499	-	_	_	
53-6	3499-3503	5201	_	_	
53-7	3504-3505	(	_	_	
53-8	3505-3509	1987	_	_	
53-9	3509-3510	)	_	_	
53-10	3510-3511	]	_	_	
53-11	3511-3512	.	_	_	

#Text=All of the foregoing publications are incorporated by reference into this application.
54-1	3513-3516	All	_	_	
54-2	3517-3519	of	_	_	
54-3	3520-3523	the	_	_	
54-4	3524-3533	foregoing	_	_	
54-5	3534-3546	publications	_	_	
54-6	3547-3550	are	_	_	
54-7	3551-3563	incorporated	_	_	
54-8	3564-3566	by	_	_	
54-9	3567-3576	reference	_	_	
54-10	3577-3581	into	_	_	
54-11	3582-3586	this	_	_	
54-12	3587-3598	application	_	_	
54-13	3598-3599	.	_	_	

#Text=Because the U3 region contains a polyadenylation signal, any deletions within this region can eliminate processing of nascent mRNA.
55-1	3600-3607	Because	_	_	
55-2	3608-3611	the	_	_	
55-3	3612-3614	U3	_	_	
55-4	3615-3621	region	_	_	
55-5	3622-3630	contains	_	_	
55-6	3631-3632	a	_	_	
55-7	3633-3648	polyadenylation	_	_	
55-8	3649-3655	signal	_	_	
55-9	3655-3656	,	_	_	
55-10	3657-3660	any	_	_	
55-11	3661-3670	deletions	_	_	
55-12	3671-3677	within	_	_	
55-13	3678-3682	this	_	_	
55-14	3683-3689	region	_	_	
55-15	3690-3693	can	_	_	
55-16	3694-3703	eliminate	_	_	
55-17	3704-3714	processing	_	_	
55-18	3715-3717	of	_	_	
55-19	3718-3725	nascent	_	_	
55-20	3726-3730	mRNA	_	_	
55-21	3730-3731	.	_	_	

#Text=In the absence of 3' RNA processing, such as polyadenylation, newly transcribed mRNA is highly unstable and, therefore, subject to immediate degradation.
56-1	3732-3734	In	_	_	
56-2	3735-3738	the	_	_	
56-3	3739-3746	absence	_	_	
56-4	3747-3749	of	_	_	
56-5	3750-3751	3	_	_	
56-6	3751-3752	'	_	_	
56-7	3753-3756	RNA	_	_	
56-8	3757-3767	processing	_	_	
56-9	3767-3768	,	_	_	
56-10	3769-3773	such	_	_	
56-11	3774-3776	as	_	_	
56-12	3777-3792	polyadenylation	_	_	
56-13	3792-3793	,	_	_	
56-14	3794-3799	newly	_	_	
56-15	3800-3811	transcribed	_	_	
56-16	3812-3816	mRNA	_	_	
56-17	3817-3819	is	_	_	
56-18	3820-3826	highly	_	_	
56-19	3827-3835	unstable	_	_	
56-20	3836-3839	and	_	_	
56-21	3839-3840	,	_	_	
56-22	3841-3850	therefore	_	_	
56-23	3850-3851	,	_	_	
56-24	3852-3859	subject	_	_	
56-25	3860-3862	to	_	_	
56-26	3863-3872	immediate	_	_	
56-27	3873-3884	degradation	_	_	
56-28	3884-3885	.	_	_	

#Text=This accounts for the observation that provirus mRNA was not detectable in a packaging cell line transfected with retrovirus DNA possessing such a deletion (Dougherty, J.
57-1	3886-3890	This	_	_	
57-2	3891-3899	accounts	_	_	
57-3	3900-3903	for	_	_	
57-4	3904-3907	the	_	_	
57-5	3908-3919	observation	_	_	
57-6	3920-3924	that	_	_	
57-7	3925-3933	provirus	_	_	
57-8	3934-3938	mRNA	_	_	
57-9	3939-3942	was	_	_	
57-10	3943-3946	not	_	_	
57-11	3947-3957	detectable	_	_	
57-12	3958-3960	in	_	_	
57-13	3961-3962	a	_	_	
57-14	3963-3972	packaging	_	_	
57-15	3973-3977	cell	_	_	
57-16	3978-3982	line	_	_	
57-17	3983-3994	transfected	_	_	
57-18	3995-3999	with	_	_	
57-19	4000-4010	retrovirus	_	_	
57-20	4011-4014	DNA	_	_	
57-21	4015-4025	possessing	_	_	
57-22	4026-4030	such	_	_	
57-23	4031-4032	a	_	_	
57-24	4033-4041	deletion	_	_	
57-25	4042-4043	(	_	_	
57-26	4043-4052	Dougherty	_	_	
57-27	4052-4053	,	_	_	
57-28	4054-4055	J	_	_	
57-29	4055-4056	.	_	_	

#Text=P. and Temin, H.
58-1	4057-4058	P	_	_	
58-2	4058-4059	.	_	_	
58-3	4060-4063	and	_	_	
58-4	4064-4069	Temin	_	_	
58-5	4069-4070	,	_	_	
58-6	4071-4072	H	_	_	
58-7	4072-4073	.	_	_	

#Text=M., Proc.
59-1	4074-4075	M	_	_	
59-2	4075-4076	.	_	_	
59-3	4076-4077	,	_	_	
59-4	4078-4082	Proc	_	_	
59-5	4082-4083	.	_	_	

#Text=Natl.
60-1	4084-4088	Natl	_	_	
60-2	4088-4089	.	_	_	

#Text=Acad.
61-1	4090-4094	Acad	_	_	
61-2	4094-4095	.	_	_	

#Text=Sci.
62-1	4096-4099	Sci	_	_	
62-2	4099-4100	.	_	_	

#Text=USA 84:1197-1201 [19871, incorporated herein by reference).
63-1	4101-4104	USA	_	_	
63-2	4105-4107	84	_	_	
63-3	4107-4108	:	_	_	
63-4	4108-4112	1197	_	_	
63-5	4112-4113	-	_	_	
63-6	4113-4117	1201	_	_	
63-7	4118-4119	[	_	_	
63-8	4119-4124	19871	_	_	
63-9	4124-4125	,	_	_	
63-10	4126-4138	incorporated	_	_	
63-11	4139-4145	herein	_	_	
63-12	4146-4148	by	_	_	
63-13	4149-4158	reference	_	_	
63-14	4158-4159	)	_	_	
63-15	4159-4160	.	_	_	

#Text=Addition of an exogenous SV40 polyadenylation signal to a site downstream from the 3' LTR has been used in an attempt to increase the virus mRNA level in the packaging cells.
64-1	4161-4169	Addition	*[1]	65-8[2_1]	
64-2	4170-4172	of	*[1]	_	
64-3	4173-4175	an	*[1]	_	
64-4	4176-4185	exogenous	*[1]	_	
64-5	4186-4190	SV40	*[1]	_	
64-6	4191-4206	polyadenylation	*[1]	_	
64-7	4207-4213	signal	*[1]	_	
64-8	4214-4216	to	*[1]	_	
64-9	4217-4218	a	*[1]	_	
64-10	4219-4223	site	*[1]	_	
64-11	4224-4234	downstream	*[1]	_	
64-12	4235-4239	from	*[1]	_	
64-13	4240-4243	the	*[1]	_	
64-14	4244-4245	3	*[1]	_	
64-15	4245-4246	'	*[1]	_	
64-16	4247-4250	LTR	*[1]	_	
64-17	4251-4254	has	*[1]	_	
64-18	4255-4259	been	*[1]	_	
64-19	4260-4264	used	*[1]	_	
64-20	4265-4267	in	*[1]	_	
64-21	4268-4270	an	*[1]	_	
64-22	4271-4278	attempt	*[1]	_	
64-23	4279-4281	to	*[1]	_	
64-24	4282-4290	increase	*[1]	_	
64-25	4291-4294	the	*[1]	_	
64-26	4295-4300	virus	*[1]	_	
64-27	4301-4305	mRNA	*[1]	_	
64-28	4306-4311	level	*[1]	_	
64-29	4312-4314	in	*[1]	_	
64-30	4315-4318	the	*[1]	_	
64-31	4319-4328	packaging	*[1]	_	
64-32	4329-4334	cells	*[1]	_	
64-33	4334-4335	.	*[1]	_	

#Text=Several problems arise from the use of this method.
65-1	4336-4343	Several	_	_	
65-2	4344-4352	problems	_	_	
65-3	4353-4358	arise	_	_	
65-4	4359-4363	from	_	_	
65-5	4364-4367	the	_	_	
65-6	4368-4371	use	_	_	
65-7	4372-4374	of	_	_	
65-8	4375-4379	this	*[2]	_	
65-9	4380-4386	method	*[2]	_	
65-10	4386-4387	.	_	_	

#Text=The exogenous polyadenylation signal results in a lengthened viral mRNA with additional U5 and SV40 polyadenylation signal sequences which are not present in the retrovirus vector RNA in the packaging cells and in the target cells.
66-1	4388-4391	The	_	_	
66-2	4392-4401	exogenous	_	_	
66-3	4402-4417	polyadenylation	_	_	
66-4	4418-4424	signal	_	_	
66-5	4425-4432	results	_	_	
66-6	4433-4435	in	_	_	
66-7	4436-4437	a	_	_	
66-8	4438-4448	lengthened	_	_	
66-9	4449-4454	viral	_	_	
66-10	4455-4459	mRNA	_	_	
66-11	4460-4464	with	_	_	
66-12	4465-4475	additional	_	_	
66-13	4476-4478	U5	_	_	
66-14	4479-4482	and	_	_	
66-15	4483-4487	SV40	_	_	
66-16	4488-4503	polyadenylation	_	_	
66-17	4504-4510	signal	_	_	
66-18	4511-4520	sequences	_	_	
66-19	4521-4526	which	_	_	
66-20	4527-4530	are	_	_	
66-21	4531-4534	not	_	_	
66-22	4535-4542	present	_	_	
66-23	4543-4545	in	_	_	
66-24	4546-4549	the	_	_	
66-25	4550-4560	retrovirus	_	_	
66-26	4561-4567	vector	_	_	
66-27	4568-4571	RNA	_	_	
66-28	4572-4574	in	_	_	
66-29	4575-4578	the	_	_	
66-30	4579-4588	packaging	_	_	
66-31	4589-4594	cells	_	_	
66-32	4595-4598	and	_	_	
66-33	4599-4601	in	_	_	
66-34	4602-4605	the	_	_	
66-35	4606-4612	target	_	_	
66-36	4613-4618	cells	_	_	
66-37	4618-4619	.	_	_	

#Text=This extra sequence can not only sterically hinder both the intermolecular and intramolecular transfer of templates during reverse transcription of the viral vector RNA, but can also decrease the packaging efficiency and the size of the exogenous nucleic acid sequence which can be inserted into the virus vector due to the size restriction of the RNA which can be packaged (Whitcomb, J.
67-1	4620-4624	This	_	_	
67-2	4625-4630	extra	_	_	
67-3	4631-4639	sequence	_	_	
67-4	4640-4643	can	_	_	
67-5	4644-4647	not	_	_	
67-6	4648-4652	only	_	_	
67-7	4653-4663	sterically	_	_	
67-8	4664-4670	hinder	_	_	
67-9	4671-4675	both	_	_	
67-10	4676-4679	the	_	_	
67-11	4680-4694	intermolecular	_	_	
67-12	4695-4698	and	_	_	
67-13	4699-4713	intramolecular	_	_	
67-14	4714-4722	transfer	_	_	
67-15	4723-4725	of	_	_	
67-16	4726-4735	templates	_	_	
67-17	4736-4742	during	_	_	
67-18	4743-4750	reverse	_	_	
67-19	4751-4764	transcription	_	_	
67-20	4765-4767	of	_	_	
67-21	4768-4771	the	_	_	
67-22	4772-4777	viral	_	_	
67-23	4778-4784	vector	_	_	
67-24	4785-4788	RNA	_	_	
67-25	4788-4789	,	_	_	
67-26	4790-4793	but	_	_	
67-27	4794-4797	can	_	_	
67-28	4798-4802	also	_	_	
67-29	4803-4811	decrease	_	_	
67-30	4812-4815	the	_	_	
67-31	4816-4825	packaging	_	_	
67-32	4826-4836	efficiency	_	_	
67-33	4837-4840	and	_	_	
67-34	4841-4844	the	_	_	
67-35	4845-4849	size	_	_	
67-36	4850-4852	of	_	_	
67-37	4853-4856	the	_	_	
67-38	4857-4866	exogenous	_	_	
67-39	4867-4874	nucleic	_	_	
67-40	4875-4879	acid	_	_	
67-41	4880-4888	sequence	_	_	
67-42	4889-4894	which	_	_	
67-43	4895-4898	can	_	_	
67-44	4899-4901	be	_	_	
67-45	4902-4910	inserted	_	_	
67-46	4911-4915	into	_	_	
67-47	4916-4919	the	_	_	
67-48	4920-4925	virus	_	_	
67-49	4926-4932	vector	_	_	
67-50	4933-4936	due	_	_	
67-51	4937-4939	to	_	_	
67-52	4940-4943	the	_	_	
67-53	4944-4948	size	_	_	
67-54	4949-4960	restriction	_	_	
67-55	4961-4963	of	_	_	
67-56	4964-4967	the	_	_	
67-57	4968-4971	RNA	_	_	
67-58	4972-4977	which	_	_	
67-59	4978-4981	can	_	_	
67-60	4982-4984	be	_	_	
67-61	4985-4993	packaged	_	_	
67-62	4994-4995	(	_	_	
67-63	4995-5003	Whitcomb	_	_	
67-64	5003-5004	,	_	_	
67-65	5005-5006	J	_	_	
67-66	5006-5007	.	_	_	

#Text=M. and Hughes, S.
68-1	5008-5009	M	_	_	
68-2	5009-5010	.	_	_	
68-3	5011-5014	and	_	_	
68-4	5015-5021	Hughes	_	_	
68-5	5021-5022	,	_	_	
68-6	5023-5024	S	_	_	
68-7	5024-5025	.	_	_	

#Text=H. 11992] Ann.
69-1	5026-5027	H	_	_	
69-2	5027-5028	.	_	_	
69-3	5029-5034	11992	_	_	
69-4	5034-5035	]	_	_	
69-5	5036-5039	Ann	_	_	
69-6	5039-5040	.	_	_	

#Text=Rev.
70-1	5041-5044	Rev	_	_	
70-2	5044-5045	.	_	_	

#Text=Cell Biol. 8:275-306, incorporated herein by reference).
71-1	5046-5050	Cell	_	_	
71-2	5051-5055	Biol	_	_	
71-3	5055-5056	.	_	_	
71-4	5057-5058	8	_	_	
71-5	5058-5059	:	_	_	
71-6	5059-5062	275	_	_	
71-7	5062-5063	-	_	_	
71-8	5063-5066	306	_	_	
71-9	5066-5067	,	_	_	
71-10	5068-5080	incorporated	_	_	
71-11	5081-5087	herein	_	_	
71-12	5088-5090	by	_	_	
71-13	5091-5100	reference	_	_	
71-14	5100-5101	)	_	_	
71-15	5101-5102	.	_	_	

#Text=In cases where reverse transcription does occur, the exogenous polyadenylation signal is lost during the process of reverse transcription and it cannot be used for polyadenylation of mRNA transcribed from an internal gene which does not contain its own polyadenylation signal.
#Text=[0006] Virus vectors such as retroviruses that can randomly integrate into a cell genome have the potential to disrupt the structure and function of cell genes.
72-1	5103-5105	In	_	_	
72-2	5106-5111	cases	_	_	
72-3	5112-5117	where	_	_	
72-4	5118-5125	reverse	_	_	
72-5	5126-5139	transcription	_	_	
72-6	5140-5144	does	_	_	
72-7	5145-5150	occur	_	_	
72-8	5150-5151	,	_	_	
72-9	5152-5155	the	_	_	
72-10	5156-5165	exogenous	_	_	
72-11	5166-5181	polyadenylation	_	_	
72-12	5182-5188	signal	_	_	
72-13	5189-5191	is	_	_	
72-14	5192-5196	lost	_	_	
72-15	5197-5203	during	_	_	
72-16	5204-5207	the	_	_	
72-17	5208-5215	process	_	_	
72-18	5216-5218	of	_	_	
72-19	5219-5226	reverse	_	_	
72-20	5227-5240	transcription	_	_	
72-21	5241-5244	and	_	_	
72-22	5245-5247	it	_	_	
72-23	5248-5254	cannot	_	_	
72-24	5255-5257	be	_	_	
72-25	5258-5262	used	_	_	
72-26	5263-5266	for	_	_	
72-27	5267-5282	polyadenylation	_	_	
72-28	5283-5285	of	_	_	
72-29	5286-5290	mRNA	_	_	
72-30	5291-5302	transcribed	_	_	
72-31	5303-5307	from	_	_	
72-32	5308-5310	an	_	_	
72-33	5311-5319	internal	_	_	
72-34	5320-5324	gene	_	_	
72-35	5325-5330	which	_	_	
72-36	5331-5335	does	_	_	
72-37	5336-5339	not	_	_	
72-38	5340-5347	contain	_	_	
72-39	5348-5351	its	_	_	
72-40	5352-5355	own	_	_	
72-41	5356-5371	polyadenylation	_	_	
72-42	5372-5378	signal	_	_	
72-43	5378-5379	.	_	_	
72-44	5380-5381	[	_	_	
72-45	5381-5385	0006	_	_	
72-46	5385-5386	]	_	_	
72-47	5387-5392	Virus	_	_	
72-48	5393-5400	vectors	_	_	
72-49	5401-5405	such	_	_	
72-50	5406-5408	as	_	_	
72-51	5409-5421	retroviruses	_	_	
72-52	5422-5426	that	_	_	
72-53	5427-5430	can	_	_	
72-54	5431-5439	randomly	_	_	
72-55	5440-5449	integrate	_	_	
72-56	5450-5454	into	_	_	
72-57	5455-5456	a	_	_	
72-58	5457-5461	cell	_	_	
72-59	5462-5468	genome	_	_	
72-60	5469-5473	have	_	_	
72-61	5474-5477	the	_	_	
72-62	5478-5487	potential	_	_	
72-63	5488-5490	to	_	_	
72-64	5491-5498	disrupt	_	_	
72-65	5499-5502	the	_	_	
72-66	5503-5512	structure	_	_	
72-67	5513-5516	and	_	_	
72-68	5517-5525	function	_	_	
72-69	5526-5528	of	_	_	
72-70	5529-5533	cell	_	_	
72-71	5534-5539	genes	_	_	
72-72	5539-5540	.	_	_	

#Text=The transcriptional elements within such a randomly integrated virus vector can activate potentially harmful genes such as oncogenes or genes triggering programmed cell death [Jaenisch, R., Harbers, K, Schnieke, A et al., Cell 32:209-216 (1983); Fung, Y.
73-1	5541-5544	The	_	_	
73-2	5545-5560	transcriptional	_	_	
73-3	5561-5569	elements	_	_	
73-4	5570-5576	within	_	_	
73-5	5577-5581	such	_	_	
73-6	5582-5583	a	_	_	
73-7	5584-5592	randomly	_	_	
73-8	5593-5603	integrated	_	_	
73-9	5604-5609	virus	_	_	
73-10	5610-5616	vector	_	_	
73-11	5617-5620	can	_	_	
73-12	5621-5629	activate	_	_	
73-13	5630-5641	potentially	_	_	
73-14	5642-5649	harmful	_	_	
73-15	5650-5655	genes	_	_	
73-16	5656-5660	such	_	_	
73-17	5661-5663	as	_	_	
73-18	5664-5673	oncogenes	_	_	
73-19	5674-5676	or	_	_	
73-20	5677-5682	genes	_	_	
73-21	5683-5693	triggering	_	_	
73-22	5694-5704	programmed	_	_	
73-23	5705-5709	cell	_	_	
73-24	5710-5715	death	_	_	
73-25	5716-5717	[	_	_	
73-26	5717-5725	Jaenisch	_	_	
73-27	5725-5726	,	_	_	
73-28	5727-5728	R	_	_	
73-29	5728-5729	.	_	_	
73-30	5729-5730	,	_	_	
73-31	5731-5738	Harbers	_	_	
73-32	5738-5739	,	_	_	
73-33	5740-5741	K	_	_	
73-34	5741-5742	,	_	_	
73-35	5743-5751	Schnieke	_	_	
73-36	5751-5752	,	_	_	
73-37	5753-5754	A	_	_	
73-38	5755-5757	et	_	_	
73-39	5758-5760	al	_	_	
73-40	5760-5761	.	_	_	
73-41	5761-5762	,	_	_	
73-42	5763-5767	Cell	_	_	
73-43	5768-5770	32	_	_	
73-44	5770-5771	:	_	_	
73-45	5771-5774	209	_	_	
73-46	5774-5775	-	_	_	
73-47	5775-5778	216	_	_	
73-48	5779-5780	(	_	_	
73-49	5780-5784	1983	_	_	
73-50	5784-5785	)	_	_	
73-51	5785-5786	;	_	_	
73-52	5787-5791	Fung	_	_	
73-53	5791-5792	,	_	_	
73-54	5793-5794	Y	_	_	
73-55	5794-5795	.	_	_	

#Text=T. et al., Proc.
74-1	5796-5797	T	_	_	
74-2	5797-5798	.	_	_	
74-3	5799-5801	et	_	_	
74-4	5802-5804	al	_	_	
74-5	5804-5805	.	_	_	
74-6	5805-5806	,	_	_	
74-7	5807-5811	Proc	_	_	
74-8	5811-5812	.	_	_	

#Text=Natl.
75-1	5813-5817	Natl	_	_	
75-2	5817-5818	.	_	_	

#Text=Acad.
76-1	5819-5823	Acad	_	_	
76-2	5823-5824	.	_	_	

#Text=Sci.
77-1	5825-5828	Sci	_	_	
77-2	5828-5829	.	_	_	

#Text=USA 78:3412-3422 (1981); Neel, B.
78-1	5830-5833	USA	_	_	
78-2	5834-5836	78	_	_	
78-3	5836-5837	:	_	_	
78-4	5837-5841	3412	_	_	
78-5	5841-5842	-	_	_	
78-6	5842-5846	3422	_	_	
78-7	5847-5848	(	_	_	
78-8	5848-5852	1981	_	_	
78-9	5852-5853	)	_	_	
78-10	5853-5854	;	_	_	
78-11	5855-5859	Neel	_	_	
78-12	5859-5860	,	_	_	
78-13	5861-5862	B	_	_	
78-14	5862-5863	.	_	_	

#Text=G. et al., Cell 23:323-334 (1981); Payne, G.
79-1	5864-5865	G	_	_	
79-2	5865-5866	.	_	_	
79-3	5867-5869	et	_	_	
79-4	5870-5872	al	_	_	
79-5	5872-5873	.	_	_	
79-6	5873-5874	,	_	_	
79-7	5875-5879	Cell	_	_	
79-8	5880-5882	23	_	_	
79-9	5882-5883	:	_	_	
79-10	5883-5886	323	_	_	
79-11	5886-5887	-	_	_	
79-12	5887-5890	334	_	_	
79-13	5891-5892	(	_	_	
79-14	5892-5896	1981	_	_	
79-15	5896-5897	)	_	_	
79-16	5897-5898	;	_	_	
79-17	5899-5904	Payne	_	_	
79-18	5904-5905	,	_	_	
79-19	5906-5907	G	_	_	
79-20	5907-5908	.	_	_	

#Text=S. et al.
80-1	5909-5910	S	_	_	
80-2	5910-5911	.	_	_	
80-3	5912-5914	et	_	_	
80-4	5915-5917	al	_	_	
80-5	5917-5918	.	_	_	

#Text=Cell 23:311-322 (1983); Lewin, B., Genes V, Oxford University Press, New York (1994)].
81-1	5919-5923	Cell	_	_	
81-2	5924-5926	23	_	_	
81-3	5926-5927	:	_	_	
81-4	5927-5930	311	_	_	
81-5	5930-5931	-	_	_	
81-6	5931-5934	322	_	_	
81-7	5935-5936	(	_	_	
81-8	5936-5940	1983	_	_	
81-9	5940-5941	)	_	_	
81-10	5941-5942	;	_	_	
81-11	5943-5948	Lewin	_	_	
81-12	5948-5949	,	_	_	
81-13	5950-5951	B	_	_	
81-14	5951-5952	.	_	_	
81-15	5952-5953	,	_	_	
81-16	5954-5959	Genes	_	_	
81-17	5960-5961	V	_	_	
81-18	5961-5962	,	_	_	
81-19	5963-5969	Oxford	_	_	
81-20	5970-5980	University	_	_	
81-21	5981-5986	Press	_	_	
81-22	5986-5987	,	_	_	
81-23	5988-5991	New	_	_	
81-24	5992-5996	York	_	_	
81-25	5997-5998	(	_	_	
81-26	5998-6002	1994	_	_	
81-27	6002-6003	)	_	_	
81-28	6003-6004	]	_	_	
81-29	6004-6005	.	_	_	

#Text=The last-mentioned book and the foregoing publications are incorporated herein by reference.
82-1	6006-6009	The	_	_	
82-2	6010-6024	last-mentioned	_	_	
82-3	6025-6029	book	_	_	
82-4	6030-6033	and	_	_	
82-5	6034-6037	the	_	_	
82-6	6038-6047	foregoing	_	_	
82-7	6048-6060	publications	_	_	
82-8	6061-6064	are	_	_	
82-9	6065-6077	incorporated	_	_	
82-10	6078-6084	herein	_	_	
82-11	6085-6087	by	_	_	
82-12	6088-6097	reference	_	_	
82-13	6097-6098	.	_	_	

#Text=While removal of the transcriptional activity of the LTRs can reduce or eliminate the risk of unwanted gene activation by the integrated virus vector, the promoters/enhancers of the exogenous nucleic acid can still act to activate cellular genes near the site of integration.
#Text=[0007] Whereas certain viruses possess useful properties for gene transfer, their use is limited by the requirement for a helper virus or by an inability to provide for stable transfer of Exogenous Nucleic Acid to a target cell.
83-1	6099-6104	While	_	_	
83-2	6105-6112	removal	_	_	
83-3	6113-6115	of	_	_	
83-4	6116-6119	the	_	_	
83-5	6120-6135	transcriptional	_	_	
83-6	6136-6144	activity	_	_	
83-7	6145-6147	of	_	_	
83-8	6148-6151	the	_	_	
83-9	6152-6156	LTRs	_	_	
83-10	6157-6160	can	_	_	
83-11	6161-6167	reduce	_	_	
83-12	6168-6170	or	_	_	
83-13	6171-6180	eliminate	_	_	
83-14	6181-6184	the	_	_	
83-15	6185-6189	risk	_	_	
83-16	6190-6192	of	_	_	
83-17	6193-6201	unwanted	_	_	
83-18	6202-6206	gene	_	_	
83-19	6207-6217	activation	_	_	
83-20	6218-6220	by	_	_	
83-21	6221-6224	the	_	_	
83-22	6225-6235	integrated	_	_	
83-23	6236-6241	virus	_	_	
83-24	6242-6248	vector	_	_	
83-25	6248-6249	,	_	_	
83-26	6250-6253	the	_	_	
83-27	6254-6263	promoters	_	_	
83-28	6263-6264	/	_	_	
83-29	6264-6273	enhancers	_	_	
83-30	6274-6276	of	_	_	
83-31	6277-6280	the	_	_	
83-32	6281-6290	exogenous	_	_	
83-33	6291-6298	nucleic	_	_	
83-34	6299-6303	acid	_	_	
83-35	6304-6307	can	_	_	
83-36	6308-6313	still	_	_	
83-37	6314-6317	act	_	_	
83-38	6318-6320	to	_	_	
83-39	6321-6329	activate	_	_	
83-40	6330-6338	cellular	_	_	
83-41	6339-6344	genes	_	_	
83-42	6345-6349	near	_	_	
83-43	6350-6353	the	_	_	
83-44	6354-6358	site	_	_	
83-45	6359-6361	of	_	_	
83-46	6362-6373	integration	_	_	
83-47	6373-6374	.	_	_	
83-48	6375-6376	[	_	_	
83-49	6376-6380	0007	_	_	
83-50	6380-6381	]	_	_	
83-51	6382-6389	Whereas	_	_	
83-52	6390-6397	certain	_	_	
83-53	6398-6405	viruses	_	_	
83-54	6406-6413	possess	_	_	
83-55	6414-6420	useful	_	_	
83-56	6421-6431	properties	_	_	
83-57	6432-6435	for	_	_	
83-58	6436-6440	gene	_	_	
83-59	6441-6449	transfer	_	_	
83-60	6449-6450	,	_	_	
83-61	6451-6456	their	_	_	
83-62	6457-6460	use	_	_	
83-63	6461-6463	is	_	_	
83-64	6464-6471	limited	_	_	
83-65	6472-6474	by	_	_	
83-66	6475-6478	the	_	_	
83-67	6479-6490	requirement	_	_	
83-68	6491-6494	for	_	_	
83-69	6495-6496	a	_	_	
83-70	6497-6503	helper	_	_	
83-71	6504-6509	virus	_	_	
83-72	6510-6512	or	_	_	
83-73	6513-6515	by	_	_	
83-74	6516-6518	an	_	_	
83-75	6519-6528	inability	_	_	
83-76	6529-6531	to	_	_	
83-77	6532-6539	provide	_	_	
83-78	6540-6543	for	_	_	
83-79	6544-6550	stable	_	_	
83-80	6551-6559	transfer	_	_	
83-81	6560-6562	of	_	_	
83-82	6563-6572	Exogenous	_	_	
83-83	6573-6580	Nucleic	_	_	
83-84	6581-6585	Acid	_	_	
83-85	6586-6588	to	_	_	
83-86	6589-6590	a	_	_	
83-87	6591-6597	target	_	_	
83-88	6598-6602	cell	_	_	
83-89	6602-6603	.	_	_	

#Text=For example, certain defective viruses can be propagated in packaging cells that provide the required packaging components but with the requirement for use of a helper virus.
84-1	6604-6607	For	_	_	
84-2	6608-6615	example	_	_	
84-3	6615-6616	,	_	_	
84-4	6617-6624	certain	_	_	
84-5	6625-6634	defective	_	_	
84-6	6635-6642	viruses	_	_	
84-7	6643-6646	can	_	_	
84-8	6647-6649	be	_	_	
84-9	6650-6660	propagated	_	_	
84-10	6661-6663	in	_	_	
84-11	6664-6673	packaging	_	_	
84-12	6674-6679	cells	_	_	
84-13	6680-6684	that	_	_	
84-14	6685-6692	provide	_	_	
84-15	6693-6696	the	_	_	
84-16	6697-6705	required	_	_	
84-17	6706-6715	packaging	_	_	
84-18	6716-6726	components	_	_	
84-19	6727-6730	but	_	_	
84-20	6731-6735	with	_	_	
84-21	6736-6739	the	_	_	
84-22	6740-6751	requirement	_	_	
84-23	6752-6755	for	_	_	
84-24	6756-6759	use	_	_	
84-25	6760-6762	of	_	_	
84-26	6763-6764	a	_	_	
84-27	6765-6771	helper	_	_	
84-28	6772-6777	virus	_	_	
84-29	6777-6778	.	_	_	

#Text=In order to insure safe use of such a virus vector preparation, however, the contaminating helper virus must be removed and the virus vector product must be extensively safety tested for the presence of any contaminating helper virus.
85-1	6779-6781	In	_	_	
85-2	6782-6787	order	_	_	
85-3	6788-6790	to	_	_	
85-4	6791-6797	insure	_	_	
85-5	6798-6802	safe	_	_	
85-6	6803-6806	use	_	_	
85-7	6807-6809	of	_	_	
85-8	6810-6814	such	_	_	
85-9	6815-6816	a	_	_	
85-10	6817-6822	virus	_	_	
85-11	6823-6829	vector	_	_	
85-12	6830-6841	preparation	_	_	
85-13	6841-6842	,	_	_	
85-14	6843-6850	however	_	_	
85-15	6850-6851	,	_	_	
85-16	6852-6855	the	_	_	
85-17	6856-6869	contaminating	_	_	
85-18	6870-6876	helper	_	_	
85-19	6877-6882	virus	_	_	
85-20	6883-6887	must	_	_	
85-21	6888-6890	be	_	_	
85-22	6891-6898	removed	_	_	
85-23	6899-6902	and	_	_	
85-24	6903-6906	the	_	_	
85-25	6907-6912	virus	_	_	
85-26	6913-6919	vector	_	_	
85-27	6920-6927	product	_	_	
85-28	6928-6932	must	_	_	
85-29	6933-6935	be	_	_	
85-30	6936-6947	extensively	_	_	
85-31	6948-6954	safety	_	_	
85-32	6955-6961	tested	_	_	
85-33	6962-6965	for	_	_	
85-34	6966-6969	the	_	_	
85-35	6970-6978	presence	_	_	
85-36	6979-6981	of	_	_	
85-37	6982-6985	any	_	_	
85-38	6986-6999	contaminating	_	_	
85-39	7000-7006	helper	_	_	
85-40	7007-7012	virus	_	_	
85-41	7012-7013	.	_	_	

#Text=The present invention overcomes these limitations by providing compositions for virus metamorphosis which can be used for propagation of virus vectors without the requirement of a helper virus.
86-1	7014-7017	The	_	_	
86-2	7018-7025	present	_	_	
86-3	7026-7035	invention	_	_	
86-4	7036-7045	overcomes	_	_	
86-5	7046-7051	these	_	_	
86-6	7052-7063	limitations	_	_	
86-7	7064-7066	by	_	_	
86-8	7067-7076	providing	_	_	
86-9	7077-7089	compositions	_	_	
86-10	7090-7093	for	_	_	
86-11	7094-7099	virus	_	_	
86-12	7100-7113	metamorphosis	_	_	
86-13	7114-7119	which	_	_	
86-14	7120-7123	can	_	_	
86-15	7124-7126	be	_	_	
86-16	7127-7131	used	_	_	
86-17	7132-7135	for	_	_	
86-18	7136-7147	propagation	_	_	
86-19	7148-7150	of	_	_	
86-20	7151-7156	virus	_	_	
86-21	7157-7164	vectors	_	_	
86-22	7165-7172	without	_	_	
86-23	7173-7176	the	_	_	
86-24	7177-7188	requirement	_	_	
86-25	7189-7191	of	_	_	
86-26	7192-7193	a	_	_	
86-27	7194-7200	helper	_	_	
86-28	7201-7206	virus	_	_	
86-29	7206-7207	.	_	_	
